The Peptide Field. CJC-1295: approval and evidence record.

Editorial review: 2026-08-02. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/cjc-1295

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=cjc-1295#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Still being studied. This review found no FDA-approved CJC-1295 product in the United States.

Exact product limits: Some products use the name CJC-1295 for different chemical forms, including different salts. Some have a chemical part called DAC, and some do not. FDA says evidence for the DAC form cannot prove the same effects for a no-DAC form. These products are not automatically the same as modified GRF 1-29 or pharmacy-made mixtures with other ingredients.

Human outcomes: Limited. Studies in people measured hormone levels. They did not test lasting health benefits.

Body effects in people: Moderate. Short studies in healthy adults found that CJC-1295 raised growth hormone and insulin-like growth factor 1 (IGF-1) for a time.

What the evidence shows: Two studies assigned healthy adults to groups by chance. Some received CJC-1295, and some received a placebo, an inactive comparison. The studies found that growth hormone and IGF-1 stayed higher for a time. Another study found changes in how growth hormone was released. These studies measured body signals, not health benefits.

What remains unknown: Higher hormone levels do not prove less body fat, more muscle, better recovery, better sleep, more energy, or a longer life. These studies did not establish those popular claims. Long-term safety is still unclear.

Safety limits: FDA says compounded CJC-1295 may pose a risk of unwanted immune reactions when given by certain routes. FDA also describes possible quality concerns, including peptide impurities and incomplete information about the active ingredient. FDA reports serious events associated with CJC-1295, including a faster heart rate and a whole-body reaction in which blood vessels widen. The small published studies did not report those serious events. Available clinical data are limited. This guide gives no dose or personal-use instructions.

Sources used in the full review (a source is not support for every claim):

PubMed · Journal of Clinical Endocrinology & Metabolism. Prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults. 2006. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/16352683/

PubMed · Journal of Clinical Endocrinology & Metabolism. Pulsatile GH secretion during continuous stimulation by CJC-1295. 2006. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/17018654/

U.S. Food and Drug Administration. Certain bulk drug substances that may present significant safety risks. 2026. Accessed 2026-07-23. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. CJC-1295 pharmacy compounding advisory review. 2024. Accessed 2026-07-23. https://www.fda.gov/media/183819/download

World Anti-Doping Agency. 2026 prohibited list. 2026. Accessed 2026-07-23. https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list

Keep the limits, review date, and sources with this record. Check the current source for changes.